Ken Griffin Organon & Co. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$18.65 - $23.03 $1.7 Million - $2.1 Million	-91,000 Reduced 28.59%	227,300 $4.35 Million
Q2 2024 Aug 14, 2024	SELL	$17.45 - $21.96 $3,490 - $4,392	-200 Reduced 0.06%	318,300 $6.59 Million
Q1 2024 May 15, 2024	SELL	$13.78 - $18.8 $1.05 Million - $1.43 Million	-76,000 Reduced 19.26%	318,500 $5.99 Million
Q4 2023 Feb 14, 2024	BUY	$10.95 - $17.32 $867,240 - $1.37 Million	79,200 Added 25.12%	394,500 $5.69 Million
Q3 2023 Nov 14, 2023	BUY	$16.59 - $23.77 $587,286 - $841,458	35,400 Added 12.65%	315,300 $5.47 Million
Q2 2023 Aug 14, 2023	BUY	$19.27 - $24.63 $859,442 - $1.1 Million	44,600 Added 18.95%	279,900 $5.82 Million
Q1 2023 May 15, 2023	SELL	$21.42 - $32.08 $1.32 Million - $1.98 Million	-61,720 Reduced 20.78%	235,300 $5.53 Million
Q4 2022 Feb 14, 2023	BUY	$23.31 - $28.61 $1.88 Million - $2.31 Million	80,580 Added 37.23%	297,020 $8.3 Million
Q3 2022 Nov 14, 2022	BUY	$23.4 - $34.25 $561,834 - $822,342	24,010 Added 12.48%	216,440 $5.07 Million

791

193M

1.71M

865K

Ticker OGN
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 254,330,000
Market Cap $3.89B
Description
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.